Publications by authors named "Andreana L Rivera"

Are you Andreana L Rivera?   Register this Author

Phosphorylated TDP-43 (pTDP-43) aggregates in the axial skeletal muscle of patients with sporadic and familial amyotrophic lateral sclerosis.
Acta Neuropathol Commun 2018 Apr 13;6(1):28. Epub 2018 Apr 13.
Institute of Academic Medicine (IAM) in the Houston Methodist Research Institute (HMRI), Houston Methodist Hospital, 6565 Fannin Street, Houston, TX, 77030, USA.

Hippocampal Sclerosis in Older Patients: Practical Examples and Guidance With a Focus on Cerebral Age-Related TDP-43 With Sclerosis.
Arch Pathol Lab Med 2017 Aug 3;141(8):1113-1126. Epub 2017 May 3.
From the Departments of Pathology and Genomic Medicine (Drs Cykowski, Powell, Rivera, and Takei), Internal Medicine (Dr Jackson), and Neurology (Dr Roman), Houston Methodist Hospital, Houston, Texas; the Department of Neurology, University of Texas Health Science Center at Houston (Dr Schulz); the Department of Pathology, Division of Neuropathology (Dr Nelson) and Sanders-Brown Center on Aging (Drs Jicha and Nelson), University of Kentucky, Lexington.

Clinical Significance of TDP-43 Neuropathology in Amyotrophic Lateral Sclerosis.
J Neuropathol Exp Neurol 2017 May;76(5):402-413
From the Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX (MDC, SZP, ALR, HT); Houston Methodist Neurological Institute, Houston Methodist Hospital, Houston, Texas (SZP, JWA, ALR, HT, SHA); Center for Biostatistics, Houston Methodist Research Institute, Houston, Texas (LP); Stanley H. Appel Department of Neurology, Houston Methodist Hospital, Houston, Texas (JWA, SHA); and Residency Program in the Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, California (EC).

Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors.
Neuro Oncol 2014 Nov 4;16(11):1541-6. Epub 2014 Jul 4.
Departments of Neurology (A.B.L., F.M.I., L.E.A., L.M.D.), Pathology (S.C.J., M.K.R.), Epidemiology & Biostatistics (A.S.R., K.S.P.), and the Brain Tumor Center, Memorial Sloan-Kettering Cancer Center, New York, New York; University of California, Los Angeles, Los Angeles, California (T.F.C.); Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas (K.D.A., A.L.R.); Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (A.F.E., D.N.L.); NorthShore University Health System, Evanston Hospital Kellogg Cancer Center, University of Chicago, Pritzker School of Medicine, Evanston, Illinois (N.A.P.); London Regional Cancer Program, London, Ontario, Canada (B.J.F.); Barrow Neurological Institute, Phoenix, Arizona (L.S.A.); University of Calgary, Calgary, Alberta, Canada (J.G.C., G.B.R.U.); Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts (P.Y.W.); Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Children's Hospital Boston, Brigham and Women's Hospital, Boston, Massachusetts (K.L.L.); University of Virginia Health System, Charlottesville, Virginia (D.S.); University of Wisconsin, Madison, Wisconsin (H.I.R., B.G.R.); University of Washington, Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, Seattle, Washington (M.C.C.); Princess Margaret Hospital, Toronto, Ontario, Canada (W.P.M.); Albany Medical Center, Albany, New York (S.A.W.); Kaiser Permanente-Los Angeles Medical Center, Los Angeles, California (R.M.G.); Clemenceau Medical Center, Beirut, Lebanon and Université Saint-Esprit de Kaslik, Byblos, Lebanon (F.G.K.).




MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma.
Neuro Oncol 2010 Feb 14;12(2):116-21. Epub 2009 Dec 14.
Departments of Pathology and Radiation-Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit-0097, Houston, TX 77030, USA.

OF